Do T cells link loss and gain-of-function mechanism in C9orf72 ALS/FTD?
This project investigates the role of T cells in the pathogenesis of ALS and FTD due to C9orf72 mutations, aiming to uncover mechanisms for new biomarkers and therapeutic targets.
Projectdetails
Introduction
Neurodegenerative diseases are the top 3 leading causes of death and are viewed now as systemic diseases. Adaptive immunity, including a T-cell response in the central nervous system (CNS), likely contributes to disease pathogenesis. How T cells are primed and recruited to the CNS is largely unexplored, due to the complexity of the process and lack of tools and animal models.
Research Focus
I will study these questions on the most common genetic form of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Here, a GGGGCC repeat expansion in the C9orf72 gene causes haploinsufficiency through reduced C9orf72 protein expression, and gain-of-function toxicities through repeat RNA and its translation to aggregating dipeptide repeats (DPRs). A synergistic role of these pathomechanisms is suspected but not clearly identified.
Hypothesis
I propose that T cells are the missing piece of the puzzle for the synergistic effects of C9orf72 haploinsufficiency and DPR toxicity. I will explore the following questions:
- Whether peripheral antigen-presenting cells (APCs) and CNS microglia present DPRs to prime antigen-specific T-cell response.
- Whether C9orf72 haploinsufficiency alters antigen presentation of microglia and APCs.
- Whether T cells mediate synergistic effects of C9orf72 haploinsufficiency and DPR toxicity.
Novel Contributions
This novel project for the first time addresses peripheral and CNS activation of T cells against DPRs in C9orf72 ALS/FTD and reveals a novel mechanism on the synergistic effect of C9orf72 haploinsufficiency and DPR toxicity.
Methodology
It offers a unique integration of neurobiological tools, immunological methods, and single-cell-level approaches. It brings solid evidence on the antigen presentation of endogenous aggregating protein to drive antigen-specific T-cell response, which will broaden the understanding of ALS/FTD and other neurodegenerative diseases.
Future Implications
This research presents a promising trajectory for the identification of new biomarkers, breakthrough therapeutic targets, and the development of novel interventions.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 1.498.610 |
Totale projectbegroting | € 1.498.610 |
Tijdlijn
Startdatum | 1-4-2024 |
Einddatum | 31-3-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- DEUTSCHES ZENTRUM FUR NEURODEGENERATIVE ERKRANKUNGEN EVpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Tuning TDP-43 self-assembly to understand physiological function and dysfunctionThe TDP-Assembly project aims to investigate the self-assembly behavior of TDP-43 RNA-binding proteins to understand their role in neurodegeneration and develop potential therapies targeting these processes. | ERC Consolid... | € 1.999.989 | 2024 | Details |
Immune mechanisms of experience induced brain plasticity: the contribution of brain resident T cellsThis project aims to explore how environmental enrichment influences brain T cells and their role in neuroplasticity, ultimately developing immunotherapy strategies for neurodevelopmental disorders. | ERC Starting... | € 1.499.650 | 2025 | Details |
Activation and switch of fates in T lymphocytes.This project aims to model the fate choices of naïve and memory CD8+ T cells using experimental immunology and systems biology to enhance vaccine design and improve responses to infections and cancer. | ERC Consolid... | € 2.625.000 | 2025 | Details |
Deciphering Neurodegenerative Disease with fast 3D imaging & functional nanoscopyThis project aims to investigate the biophysical mechanisms of protein aggregation in Huntington's Disease using advanced imaging techniques to enhance understanding of neurodegenerative processes. | ERC Starting... | € 1.500.000 | 2024 | Details |
The origin and impact of impaired ubiquitin signaling in the degeneration of neuronsThis project aims to investigate dysregulated ubiquitin signaling as an early cause of neurodegeneration, using innovative human neuronal models to enhance understanding and treatment of Alzheimer's disease. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Tuning TDP-43 self-assembly to understand physiological function and dysfunction
The TDP-Assembly project aims to investigate the self-assembly behavior of TDP-43 RNA-binding proteins to understand their role in neurodegeneration and develop potential therapies targeting these processes.
Immune mechanisms of experience induced brain plasticity: the contribution of brain resident T cells
This project aims to explore how environmental enrichment influences brain T cells and their role in neuroplasticity, ultimately developing immunotherapy strategies for neurodevelopmental disorders.
Activation and switch of fates in T lymphocytes.
This project aims to model the fate choices of naïve and memory CD8+ T cells using experimental immunology and systems biology to enhance vaccine design and improve responses to infections and cancer.
Deciphering Neurodegenerative Disease with fast 3D imaging & functional nanoscopy
This project aims to investigate the biophysical mechanisms of protein aggregation in Huntington's Disease using advanced imaging techniques to enhance understanding of neurodegenerative processes.
The origin and impact of impaired ubiquitin signaling in the degeneration of neurons
This project aims to investigate dysregulated ubiquitin signaling as an early cause of neurodegeneration, using innovative human neuronal models to enhance understanding and treatment of Alzheimer's disease.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stageDeveloping a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships. | EIC Transition | € 2.499.810 | 2022 | Details |
Advancing a vaccine targeting genetic amyotrophic lateral sclerosis (C9orf72 ALS) to the clinical stage
Developing a poly-GA peptide vaccine to reduce protein aggregation and motor deficits in C9orf72 ALS, aiming for clinical evaluation and market entry through strategic partnerships.